DYNACIRC CR Drug Patent Profile

When do Dynacirc Cr patents expire, and what generic alternatives are available?

Dynacirc Cr is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in DYNACIRC CR is isradipine. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the isradipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dynacirc Cr

A generic version of DYNACIRC CR was approved as isradipine by WATSON LABS TEVA on January 5^th, 2006.

Summary for DYNACIRC CR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	3
Patent Applications:	5,066
DailyMed Link:	DYNACIRC CR at DailyMed

Recent Clinical Trials for DYNACIRC CR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Texas at Austin	Early Phase 1
National Institute on Drug Abuse (NIDA)	Early Phase 1
The Parkinson Study Group	Phase 2

See all DYNACIRC CR clinical trials

US Patents and Regulatory Information for DYNACIRC CR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-001	Jun 1, 1994		DISCN	Yes	No
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-002	Jun 1, 1994		DISCN	Yes	No

Expired US Patents for DYNACIRC CR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-002	Jun 1, 1994	4,946,687
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-001	Jun 1, 1994	4,950,486
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-002	Jun 1, 1994	4,816,263

International Patents for DYNACIRC CR

See the table below for patents covering DYNACIRC CR around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	2140687	OSMOTIC DRUG DELIVERY SYSTEM
Italy	1234215	FORMA DI DOSAGGIO PER IL TRATTAMENTO DI MALATTIE CARDIOVASCOLARI
Canada	1131228	BENZOXADIAZOLES ET BENZOTHIADIAZOLES, LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES QUI EN CONTIENNENT (BENZOXADIAZOLES AND BENZOTHIADIAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM)

DYNACIRC CR Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Dynacirc CR

Introduction to Dynacirc CR

Dynacirc CR, a controlled-release formulation of the calcium channel blocker isradipine, is used to manage hypertension. Here, we will delve into the market dynamics and financial aspects associated with this medication.

Therapeutic Use and Mechanism

Dynacirc CR is indicated for the treatment of high blood pressure, either alone or in combination with other medications such as thiazide diuretics. It works by affecting the movement of calcium into the cells of the heart and blood vessels, thereby relaxing blood vessels and increasing blood and oxygen supply to the heart while reducing its workload[3][4].

Market Positioning

Competitive Landscape

The market for calcium channel blockers is competitive, with several other drugs available for managing hypertension. However, Dynacirc CR's controlled-release formulation provides a unique advantage by offering a steady and consistent delivery of the medication, which can improve patient compliance and reduce side effects associated with peak and trough levels of the drug[3].

Patient Population

Dynacirc CR is prescribed for patients with hypertension, a condition that affects a significant portion of the population worldwide. The drug's efficacy in managing blood pressure makes it a valuable option for both primary care physicians and specialists.

Side Effects and Tolerability

The side effect profile of Dynacirc CR is generally favorable, with common adverse reactions including headache, dizziness, edema, and palpitations. These effects are often mild and transient, although dose-related edema is more common at higher doses[3].

Regulatory Status

The Dynacirc CR brand name has been discontinued in the U.S., but generic versions of isradipine may still be available. This change can impact the market dynamics, as generic alternatives often reduce the market share of branded products[4].

Financial Trajectory

Sales and Revenue

Given the discontinuation of the branded version, the financial trajectory for Dynacirc CR is likely to be influenced by the availability and market penetration of generic isradipine. Generic drugs typically have lower prices, which can lead to increased volume sales but reduced revenue per unit.

Cost and Pricing

The cost of Dynacirc CR, especially in its generic form, is generally lower compared to other calcium channel blockers. This pricing strategy can make it more accessible to a broader patient population, potentially increasing its market share despite the loss of brand name recognition.

Impact of Generic Competition

The introduction of generic isradipine can significantly alter the financial landscape for Dynacirc CR. Generic competition often leads to a reduction in prices, which can result in lower revenue for the original manufacturer but may also increase the overall market size due to higher affordability.

Clinical Trials and Long-Term Studies

Clinical trials and long-term studies have shown that Dynacirc CR is effective and well-tolerated over extended periods. These studies support the drug's continued use, even in the face of generic competition, as they highlight its safety and efficacy profile[3].

Geriatric Use and Pharmacokinetics

Elderly patients, who often have decreased hepatic, renal, or cardiac function, may require cautious dose selection due to the higher bioavailability of isradipine in this population. This demographic consideration can influence prescribing patterns and market dynamics[3].

Drug Interactions and Co-administration

Dynacirc CR can be safely co-administered with other medications such as nitroglycerin and hydrochlorothiazide, which is beneficial for patients with complex hypertension management needs. This compatibility can enhance its market position by offering flexibility in treatment regimens[1].

Key Takeaways

• Therapeutic Efficacy: Dynacirc CR is effective in managing hypertension with a favorable side effect profile.
• Market Competition: The discontinuation of the branded version and the availability of generic isradipine will significantly impact market dynamics.
• Financial Impact: Generic competition will likely reduce revenue per unit but may increase overall sales volume.
• Regulatory Status: The availability of generic versions will continue to influence the drug's market presence.
• Patient Population: The drug remains a valuable option for managing hypertension, especially in elderly patients and those requiring combination therapy.

FAQs

What is Dynacirc CR used for?

Dynacirc CR is used to treat high blood pressure (hypertension) and can be used alone or in combination with other medications.

What are the common side effects of Dynacirc CR?

Common side effects include headache, dizziness, edema, palpitations, and fatigue, with edema being more common at higher doses.

Is Dynacirc CR still available under its brand name?

No, the Dynacirc CR brand name has been discontinued in the U.S., but generic versions of isradipine may still be available.

How does Dynacirc CR compare to other calcium channel blockers?

Dynacirc CR offers a controlled-release formulation, providing a steady and consistent delivery of the medication, which can improve patient compliance and reduce side effects.

Can Dynacirc CR be used in elderly patients?

Yes, but dose selection should be cautious due to the higher bioavailability of isradipine in elderly patients.

Cited Sources:

1. RxList - Dynacirc (Isradipine): Side Effects, Uses, Dosage[1]
2. Investing News - Dynacor Group Reports Record Quarterly Sales[2]
3. RxList - Dynacirc CR (Isradipine): Side Effects, Uses, Dosage[3]
4. Drugs.com - Dynacirc CR Advanced Patient Information[4]